Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis
2018; Elsevier BV; Volume: 19; Issue: 1 Linguagem: Inglês
10.1016/s1473-3099(18)30596-6
ISSN1474-4457
AutoresRobert J. Commons, J. A. Simpson, Kamala Thriemer, Mohammad Sharif Hossain, Nicola Davies, Georgina Humphreys, Carol Hopkins Sibley, Philippe J. Guérin, Ric N. Price,
Tópico(s)Drug-Induced Hepatotoxicity and Protection
ResumoA 14-day course of primaquine is used for radical cure of Plasmodium vivax and Plasmodium ovale malaria only. We quantified the risk of P vivax parasitaemia after treatment of Plasmodium falciparum with commonly used antimalarial drugs to assess the potential benefits of radical cure for all patients with uncomplicated malaria in co-endemic regions.
Referência(s)